Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.48 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8669278 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| SCHEMBL6946044 | 0.92 | SLC6A4 (0.43) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| Fumaric Acid SCHEMBL8671237 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| Fumaric Acid SCHEMBL8671240 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| SCHEMBL6948974 | 0.83 | DRD4 (0.45) | SMN1; SMN2SLC6A4KDM4EALDH1A1HTT | |
| Fumaric Acid SCHEMBL6949525 | 0.82 | MEN1 (0.48) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| Fumaric Acid SCHEMBL6949519 | 0.82 | MEN1 (0.48) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| Fumaric Acid SCHEMBL8671252 | 0.81 | MEN1 (0.48) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| Fumaric Acid SCHEMBL8671251 | 0.81 | MEN1 (0.48) | SMN1; SMN2MEN1LMNAKMT2ABLM | |
| SCHEMBL6947216 | 0.81 | SLC6A4 (0.55) | SMN1; SMN2MEN1LMNAKMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5770740-A | TREATING DEPRESSION AND OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5696142-A | TREATING DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5686447-A | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5686483-A | TREATING DEPRESSION AND OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5686446-A | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5684021-A | Aminoalkyloximes for treating depression and affective disorders | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5665756-A | Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders | HOECHST MARION ROUSSEL, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5648367-A | ANTIDEPRESANTS, OBSESSIVE-COMPULSIVE DISORDER | HOECHST MARION ROUSSEL, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0709378-A2 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-05-01 | — | — | EP | disclosed |